Medtech Leaders Speak Out On Impact of Global Tariffs
Some Medtech companies recently addressed the potential impact of global tariffs in their Q1 2025 earnings calls. Johnson & Johnson and Abbott were among the first to speak on the implications...
Teva v. Amneal Oral Arguments and Claim Construction Order: Recent Developments in the Ongoing Debate Over the Orange Book Listing of Device Patents
As the FTC continues to crack down on pharmaceutical manufacturers’ allegedly improper listing of patents in the FDA Orange Book, counsel for Teva and Amneal presented oral arguments in the Court of Appeals for the Federal Circuit on November 8,...
An Expert Witness Need Not Have Been a Posita at the Time of the Invention
OSSEO IMAGING, LLC v. PLANMECA USA INC.
Before Dyk, Clevenger, and Stoll. Appeal from the United States District Court for the District of Delaware.
Summary: An expert witness can testify from the perspective of a POSITA at the time of the invention even if they did not qualify as a POSITA until later.
Understanding the Dangers of Counterfeit Drugs Through the Lens of Fake Ozempic
The June 2024 issue of Vanity Fair included the provocative headline: “Why Counterfeit Ozempic Is a Global-Growth Industry." Novo Nordisk’s patented drug Ozempic® (semaglutide injection) was first approved by the FDA in 2017 for the treatment of type 2 diabetes. A few years later, clinical trials demonstrated that Ozempic® could also be used for weight loss in individuals without diabetes who had previously struggled to lose weight. News of the “miraculous weight loss” achieved with Ozempic® (and its sister drug Wegovy®) led to widespread demand for the drug and global shortages.
